Metrics as of 10/17/2026, 08:32 AM (Berlin time), refresh in progress.
TScan Therapeutics Stock
TScan Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Gavin MacBeath
- Employees
- 138
- Market cap
- $15 M
- IPO
- 16/07/2021
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome…
TScan Therapeutics stock: price history
1D
-3.5%
1W
-2.9%
1M
-30.2%
6M
-80.6%
YTD
-76.9%
1Y
-90.7%
2Y
-95.8%
5Y
-96.6%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~22% stronger price swings than usual
Ask the agents about TScan Therapeutics
Analyst assessment of TScan Therapeutics
PRICE TARGET LOW
US$1.00
CONSENSUS
US$1.00
MEDIAN
US$1.00
PRICE TARGET HIGH
US$1.00
0
STRONG BUY
4
BUY
4
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 08/09/2026
TScan Therapeutics stock metrics
P/E
-0.25
P/B
0.43
EV/EBITDA
-0.05
RETURN ON EQUITY
-44.0%
NET MARGIN
-2,888.6%
DEBT/EQUITY
1.32
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.6%
FLOAT SHARES
54,360,318
AVG. DAILY VOLUME (30D)
798,323
Insider transactions (SEC)
ZDRAVESKI ZORAN
MacBeath Gavin
Institutional holders
Comparable stocks
Frequently asked questions about TScan Therapeutics stock
What does TScan Therapeutics do?
TScan Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Gavin MacBeath, the company employs around 138 people.
The IPO was on 16/07/2021; the stock trades on NASDAQ under the ticker TCRX.
What do analysts say about TScan Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 08/09/2026).
The average price target is US$1.00, ranging from US$1.00 to US$1.00, with a median of US$1.00.
This is an external assessment, not a statement by Market Jury.
When does TScan Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 22% stronger than usual.
Does TScan Therapeutics pay a dividend?
No, TScan Therapeutics currently does not pay a dividend.
Which stocks are comparable to TScan Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get TScan Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess TScan Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.